{"name":"Senju USA, Inc.","slug":"senju-usa-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Olopatadine 0.2%","genericName":"Olopatadine 0.2%","slug":"olopatadine-0-2","indication":"Other","status":"marketed"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Placebo TDS","genericName":"Placebo TDS","slug":"placebo-tds","indication":"Treatment of dry eye","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"SUN-131 1.5% TDS","genericName":"SUN-131 1.5% TDS","slug":"sun-131-1-5-tds","indication":"Bacterial conjunctivitis","status":"phase_3"}]}],"pipeline":[{"name":"Olopatadine 0.2%","genericName":"Olopatadine 0.2%","slug":"olopatadine-0-2","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Placebo TDS","genericName":"Placebo TDS","slug":"placebo-tds","phase":"phase_3","mechanism":"Small molecule","indications":["Treatment of dry eye"],"catalyst":""},{"name":"SUN-131 1.5% TDS","genericName":"SUN-131 1.5% TDS","slug":"sun-131-1-5-tds","phase":"phase_3","mechanism":"SUN-131 1.5% TDS is a topical sulfonamide antibiotic used to treat bacterial conjunctivitis.","indications":["Bacterial conjunctivitis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxNOTV3aUdPNzZOV1N0SzNOVEtvMnpKZ3RXNnlod2pBZ3VvN1NMTzJFbEJCcWR0NGpxYWdaNXF0WkZnUG1iNndXeWhwcWM0M29sU1YySUMwVVU5Sy1uUTg0QXNkLTN5VEZlUTlDOFB5dE9zcDEyWHByQU5iMVRvMmtaSXpJWHR4NnJSSUtBQw?oc=5","date":"2024-03-11","type":"pipeline","source":"Fierce Pharma","summary":"The top 10 drugs losing US exclusivity in 2024 - Fierce Pharma","headline":"The top 10 drugs losing US exclusivity in 2024","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAJBVV95cUxQSWV4VUoxTzhYVTdwbWEyUjJBdUFBUTJWMEl0dTY1R1BZRzNJN242SDZNR0tDcEg5Snk1bjlMRmlqUXBJNDBpV2o0SmdDcTFkN0hWQlNOaFI5ZUw3N2RJVmJXOXE4VFV3U2hyTE1MYk01b2dyNU5HdFA4OXAtNnJIeF8yVjdiOUM2bW9BdU9zZTJ2bHVXR0hkNUQzejJlME9xRlpTRTgzWmxQRWxlaWYzZ2dnZzE3TDNteVFUcXlTZkFjQU1xSXVVby1WNDlZWnNxWkVmbmo1VnBTWWFaTnhwN0c5Q0c1X00xTXFjdS1qZmVjZzJCbFpDSkFwX2IyNTZFYllBeGNkS2M3OGNGLThYT2dFT1psU0tWTGZGaERESW1pRkZDTWt6Q1BveGFJVkwzeVdPdUh3cVd0Rlo5VmVJeQ?oc=5","date":"2023-06-13","type":"deal","source":"Via TT","summary":"Senju Pharmaceutical and Novaliq Enter Into License Agreement For NOV03 (Perfluorohexyloctane Ophthalmic Solution) For the Treatment of Dry Eye Disease in Japan - Via TT","headline":"Senju Pharmaceutical and Novaliq Enter Into License Agreement For NOV03 (Perfluorohexyloctane Ophthalmic Solution) For t","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTFBJeWVUNjBHUUNXZi1OYUl3WVZfdzdYWXpia19nNWkzZVJFUWg5S2cxM2gyM3YtTEtQVldLTW5vVVdZd0pmcDJUc01ybTdTZHVnMjNueUNmSFlQdkVPSzNqWnNxRmpYdEM5?oc=5","date":"2022-05-19","type":"pipeline","source":"Wiley Online Library","summary":"Presumed congenital nictitating membrane dysplasia in a Japanese white rabbit - Wiley Online Library","headline":"Presumed congenital nictitating membrane dysplasia in a Japanese white rabbit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE43a001QU45NUVFVGUyaXc2UmlZYTFROUIzdmwwdVJpckV0dnZiVmppLWRqU01EVWZ6UEJGbGI4aGJsejZtWjFvUE14ODJzZkpJdEZmVjh2WlUwMDFQQ3NFS0hPNjdjd1ZyYzZsQW9OOGhVSkptUEpjYzZqOG5xUQ?oc=5","date":"2019-05-15","type":"patent","source":"Patently-O","summary":"Federal Circuit has No Opinion; Senju Asks the Supreme Court for Its - Patently-O","headline":"Federal Circuit has No Opinion; Senju Asks the Supreme Court for Its - Patently","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE92TTE1Nnk3QmdyNzZNMkVmcS15MTUyTU5mMzJuY0tYNmN4UUJ4dFlfT1VWeEdqZWtMcDFIUlRnWlNsVW1DMVdwSVNTdGRWTzNlN2s3YTcwREpRbDVPcldMMzhFNDJhalBtcEZraA?oc=5","date":"2018-06-20","type":"regulatory","source":"ARVO Journals","summary":"Inhibitory Effect of Ketotifen Transdermal Patch, A Novel Ophthalmic Formulation of Ketotifen, on Histamine-Induced Conjunctival Edema in Guinea Pigs | IOVS | ARVO Journals - ARVO Journals","headline":"Inhibitory Effect of Ketotifen Transdermal Patch, A Novel Ophthalmic Formulation of Ketotifen, on Histamine-Induced Conj","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTE5NMkQtZUdWd1BfbUlrX0NPZW8tOVI4dDFFUl9mMnVSMFhLUXJ2M0dUeUlzV1RHT0VKSDRzMkFyQUhrMXpqSjJtcGZ2amhNWVJrSU1nOUxIRWh3WWZ4NDIzaGN0bU5RbTdhMzluNGJpRTY4dXNLdDBR?oc=5","date":"2015-01-26","type":"pipeline","source":"JD Supra","summary":"Court Report - January 2015 #2 | McDonnell Boehnen Hulbert & Berghoff LLP - JD Supra","headline":"Court Report - January 2015 #2 | McDonnell Boehnen Hulbert & Berghoff LLP","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"marketed":1,"phase_3":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}